Lyka Labs Limited
Bombay Stock ExchangeTotal Valuation
Lyka Labs Limited carries a market capitalization of 2.56B, placing it among publicly traded companies globally. Its enterprise value stands at 2.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.56B |
| Enterprise Value | 2.02B |
Share Statistics
Lyka Labs Limited currently has 35.69M shares outstanding.
| Shares Outstanding | 35.69M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Lyka Labs Limited trades at a trailing price-to-earnings ratio of 225.55. The price-to-sales ratio is 1.26, and the price-to-book ratio stands at 4.53.
| PE Ratio | 225.55 |
| PS Ratio | 1.26 |
| PB Ratio | 4.53 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Lyka Labs Limited trades at an EV/EBITDA multiple of 165.86 and an EV/FCF ratio of 72.12. The EV/Sales ratio of 1.57 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 165.86 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.57 |
| EV / EBITDA | 165.86 |
| EV / EBIT | 165.86 |
| EV / FCF | 72.12 |
Financial Position
Lyka Labs Limited maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 53.80, indicating elevated leverage, while an interest coverage ratio of -3.83 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.17 |
| Quick Ratio | 0.13 |
| Debt / Equity | 53.80 |
| Debt / EBITDA | -4.03 |
| Interest Coverage | -3.83 |
Financial Efficiency
| Return on Equity (ROE) | 5.73 |
| Return on Assets (ROA) | -5.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.85 |
Taxes
Over the trailing twelve months, Lyka Labs Limited has paid -13.44M in income taxes, reflecting an effective tax rate of 26.30.
| Income Tax | -13.44M |
| Effective Tax Rate | 26.30 |
Stock Price Statistics
Lyka Labs Limited's stock has declined approximately -35.11071% over the past 52 weeks. The 50-day moving average sits at 77.12, while the 200-day moving average is 98.15.
| Beta (5Y) | N/A |
| 52-Week Price Change | -35.11071% |
| 50-Day Moving Average | 77.12 |
| 200-Day Moving Average | 98.15 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lyka Labs Limited generated 1.28B in revenue and converted that into -100.32M in net income, yielding earnings per share of -2.89. EBITDA reached -121.17M, while operating income came in at -121.17M.
| Revenue | 1.28B |
| Gross Profit | 782.46M |
| Operating Income | -121.17M |
| Pretax Income | -117.79M |
| Net Income | -100.32M |
| EBITDA | -121.17M |
| EBIT | -121.17M |
| Earnings Per Share (EPS) | -2.89 |
Balance Sheet
Lyka Labs Limited holds 69.17M in cash and equivalents against 488.69M in total debt, resulting in a net debt position of 469.97M. Total book value stands at 356.90M, with working capital of 93.79M providing operational flexibility.
| Cash & Cash Equivalents | 69.17M |
| Total Debt | 488.69M |
| Net Debt | 469.97M |
| Equity (Book Value) | 356.90M |
| Book Value Per Share | 9.88 |
| Working Capital | 93.79M |
Margins
Lyka Labs Limited operates with a gross margin of 60.92, reflecting its pricing power and cost economics. The operating margin of -9.43 and net profit margin of -7.81 provide insight into operational efficiency.
| Gross Margin | 60.92 |
| Operating Margin | -9.43 |
| Pretax Margin | -9.17 |
| Profit Margin | -7.81 |
| EBITDA Margin | -9.43 |
Scores
Lyka Labs Limited posts an Altman Z-Score of 1.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.75 |